In contrast, Thomas et al. reported no difference in time to progression for EGFR‐positive NSCLC with CNS metastases when EGFR–TKI was combined with radiotherapy compared with EGFR–TKI alone; thus, the combination of radiotherapy might not be beneficial in CNS metastatic recurrence [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.